शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEUnjha Formulations Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 10 Nov, 2025 · 14:13 IST

Regulation 33 of SEBI LODR ,2015

Pat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+6.8%Reaction day
₹23.65
prior close
₹25.50
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.4%+7.1% vs market
Pharmaceuticals peers, median of 155sector-0.1%+6.9% vs sector

On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 6.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-2.8
10m
-2.8
15m
-2.0
30m
-2.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+6.8-0.4+7.1-0.1+6.9
Next day
+8.8-0.6+9.5-0.8+9.6
2d
+6.6+0.3+6.3+0.2+6.4
3d
+14.1+0.2+13.9-0.0+14.1
4d
+14.2+0.1+14.1+0.2+14.0
5d
+14.0+0.7+13.2+0.3+13.7
1w
+11.6-0.3+11.9-0.9+12.5
15d
+2.9-2.0+4.9-1.5+4.3
1m
+6.8-5.7+12.5-3.8+10.6
2m
+1.5-7.8+9.3-6.5+8.0
3m
-4.7-4.6-0.0-6.9+2.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Unjha Formulations reported total income from operations of ₹434.74 lakhs for Q2 FY26, up about 14% from ₹380.66 lakhs in Q2 FY25. The company swung to an operating profit of ₹81.78 lakhs in Q2 FY26, compared to a loss of ₹11.06 lakhs in the same quarter last year, with EPS of ₹1.83 versus a negative ₹0.25. For the half year ended September 2025, total income rose to ₹798.15 lakhs and PAT more than doubled to ₹120.78 lakhs from ₹58.82 lakhs in H1 FY25. Net cash from operating activities was strongly positive at ₹103.99 lakhs, lifting cash balances to ₹160.08 lakhs. The auditor (Jain & Golechha) issued an unqualified limited review report.

Likely market impact

The sharp return to profitability, doubling of half-yearly PAT, and strong operating cash flow are positive signals for shareholders, though other equity remains negative (₹134.17 lakhs) reflecting past accumulated losses.